What if your dosage adjustments or DBS adjustments could be supported by automatic, reliable clinical biomarkers from Parkinson’s disease symptoms?
The Stardots ANLIVA™ platform aims to make the most of precision treatments for mid-to late-stage Parkinson’s disease. As we move closer to an official release, we will provide early access to a select few hospitals.
By becoming a partner clinic, you help shape the future of Parkinson’s care. We are currently seeking partners in the EU to support clinical trials, early evaluation, and feedback.
Interested in learning more? Please leave your contact information or get in touch with us.